For information about COVID-19, including symptoms and prevention, please read our COVID-19 patient guide. Please also consider supporting Weill Cornell Medicine’s efforts against the pandemic.
Population Health Sciences

You are here

Publications

Found 18 results
[ Author(Asc)] Title Type Year
Filters: First Letter Of Last Name is P  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Prigerson HG, Bao Y, Shah MA, M Paulk E, LeBlanc TW, Schneider BJ, Garrido MM, M Reid C, Berlin DA, Adelson KB et al..  2015.  Chemotherapy Use, Performance Status, and Quality of Life at the End of Life.. JAMA Oncol. 1(6):778-84.
Press MJ, Gerber LM, Peng TR, Pesko MF, Feldman PH, Ouchida K, Sridharan S, Bao Y, Barron Y, Casalino LP.  2015.  Post-Discharge Communication Between Home Health Nurses and Physicians: Measurement, Quality, and Outcomes.. J Am Geriatr Soc. 63(7):1299-305.
Ponirakis G, Elhadd T, Chinnaiyan S, Dabbous Z, Siddiqui M, Al-Muhannadi H, Petropoulos IN, Khan A, Ashawesh KAE, Dukhan KMO et al..  2020.  Prevalence and management of diabetic neuropathy in secondary care in Qatar.. Diabetes Metab Res Rev. 36(4):e3286.
Ponirakis G, Abdul-Ghani MA, Jayyousi A, Almuhannadi H, Petropoulos IN, Khan A, Gad H, Migahid O, Megahed A, DeFronzo R et al..  2020.  Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study.. BMJ Open Diabetes Res Care. 8(1)
Ponirakis G, Elhadd T, Chinnaiyan S, Dabbous Z, Siddiqui M, Al-Muhannadi H, Petropoulos IN, Khan A, Ashawesh KAE, Dukhan KMO et al..  2020.  Prevalence and management of diabetic neuropathy in secondary care in Qatar.. Diabetes Metab Res Rev. 36(4):e3286.
Phongtankuel V, Johnson P, Reid MC, Adelman RD, Grinspan Z, Unruh MA, Abramson E.  2017.  Risk Factors for Hospitalization of Home Hospice Enrollees Development and Validation of a Predictive Tool.. Am J Hosp Palliat Care. 34(9):806-813.
Pesko MF, Maclean JCatherine, Kaplan CM, Hill SC.  2017.  Trends over time in enrollment in non-group health insurance plans by tobacco use in the United States.. Prev Med Rep. 7:46-49.
Pesko MF, Kenkel DS, Wang H, Hughes JM.  2016.  The effect of potential electronic nicotine delivery system regulations on nicotine product selection.. Addiction. 111(4):734-44.
Pesko MF, Baum CF.  2016.  The self-medication hypothesis: Evidence from terrorism and cigarette accessibility.. Econ Hum Biol. 22:94-102.
Pesko MF, Robarts AMT.  2017.  Adolescent Tobacco Use in Urban Versus Rural Areas of the United States: The Influence of Tobacco Control Policy Environments.. J Adolesc Health. 61(1):70-76.
Pesko MF, Ryan AM, Shortell SM, Copeland KR, Ramsay PP, Sun X, Mendelsohn JL, Rittenhouse DR, Casalino LP.  2017.  Spending per Medicare Beneficiary Is Higher in Hospital-Owned Small- and Medium-Sized Physician Practices.. Health Serv Res.
Pesko MF, Xu X, Tynan MA, Gerzoff RB, Malarcher AM, Pechacek TF.  2014.  Per-pack price reductions available from different cigarette purchasing strategies: United States, 2009-2010.. Prev Med. 63:13-9.
Pesko MF, Gerber LM, Peng TR, Press MJ.  2018.  Home Health Care: Nurse-Physician Communication, Patient Severity, and Hospital Readmission.. Health Serv Res. 53(2):1008-1024.
Pesko MF, Hughes JM, Faisal FS.  2016.  The influence of electronic cigarette age purchasing restrictions on adolescent tobacco and marijuana use.. Prev Med. 87:207-212.
Perumalswami CR, Mullangi S, Jagsi R.  2019.  The Role of Medicare Reimbursement in Determining Access to Palliative Radiotherapy During Hospice Care.. JAMA Oncol.
Patel AD, Haridas B, Grinspan ZM, Stevens J.  2017.  Utility of long-term video-EEG monitoring for children with staring.. Epilepsy Behav. 68:186-191.
Patel N, Golan R, Halpern JA, Sun T, Asafu-Adjei ADenise, Chughtai B, Stahl P, Sedrakyan A, Kashanian JA.  2019.  A Contemporary Analysis of Dual Inflatable Penile Prosthesis and Artificial Urinary Sphincter Outcomes.. J Urol. 201(1):141-146.
Pandya A, Soeteman DI, Gupta A, Kamel H, Mushlin AI, Rosenthal MB.  2020.  Can Pay-for Performance Incentive Levels be Determined Using a Cost-Effectiveness Framework? Circ Cardiovasc Qual Outcomes. 13(7):e006492.